Mural Oncology Plc (MURA) Quarterly Balance Sheets

Quarterly · GAAP · USD millions
Access MURA Annual Balance Sheets →
Examining balance sheet movements between Mural Oncology Plc and Sep 30 2024 reveals how Sep 30 2025 adjusts its asset composition and liability profile.
Quarterly Report, GAAP in USD millions
ITEM
(Sep 30 2025)
(Jun 30 2025) (Mar 31 2025) (Dec 31 2024) (Sep 30 2024)
Assets
Cash & cash equivalent58.87
Marketable Securities, Total MA0.00
Cash & Short-term Investments58.00
Nontrade Receivables, Current0.00
Other current assets2.08
Prepaid Expense, Current AS1.21
Total Current Assets62.16
Equipment/Property/Plant Net0.47
Other Assets3.13
Restricted Cash Current1.71
Operating Lease Right Of Use Asset3.13
Total Assets65.76
Liabilities
Accounts Payable, Current AC0.00
Accrued Liabilities, Current AC6.79
Other current liabilities3.74
Total Current Liabilities10.53
Total Long-term Debt0.00
Other longterm liabilities0.04
Operating Lease Liability Current3.51
Operating Lease Liability Noncurrent0.04
Total Liabilities10.57
Stockholders' Equity
Unrealized Gain Loss On Marketable Securities-
Common Stock Value0.17
Additional Paid In Capital Common Stock299.21
Retained Earnings / Accumulated Deficit-244.20
Other Equity0.00
Common Stockholder's Equity55.19
Total Stockholder's Equity55.19
Liabilities & Stockholder's Equity65.76
4 historic quarters locked

Sign in to unlock the full Mural Oncology Plc balance sheet history.

About Mural Oncology Plc Quarterly Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC 10-Q filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.
  • Accession: 0001193125-25-268122

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.